Pharmaceutical manufacturers started reducing prices for HIV-drugs

14-02-2017 | 16:44

Price reduction is based upon the findings of the second phase of an international comparative price survey conducted by FAS

At the second stage of the international comparative analysis FAS was studying prices for the drugs used to treat patients with HIV, hepatitis B and C, and tuberculosis with multiple drug resistance.

The Antimonopoly Service established that prices on 95 drug positions in other countries (including the reference countries for Russia) were below the ceiling ex-works manufacturer prices registered in the Russian Federation.

FAS proposed to all owners and holders of the registration certificates for the above drugs to take advantage of the right to file applications to decrease the registered ceiling ex-works prices.

Some pharmaceutical companies started reducing the drug prices voluntarily. As of 9 February 2017, 30 earlier registered prices in the State Register of ceiling Ex-Works Prices were decreased.

Among the first companies reducing their prices are: “Teva” (Israel), “Sandoz” (Slovenia), “EBV” (Germany), “GlaxoSmithKline Trading” (the UK), “Roche” (Switzerland), “ViiV Healthcare” (the UK), “Macleods Pharmaceuticals Ltd” (India), “Panacea Biotec Ltd.” (India) and “Plethico Pharmaceuticals Ltd” (India). The reduction on average reached 30 % of earlier registered prices. The biggest reduction in RUB (4800 Rub per consumer packaging) was observed for “Plevolox” (presentation – tablets) made by “Plethico Pharmaceuticals Ltd” (India).

Head of FAS Department for Control over Social Sphere and Trade, Timophey Nizhegordtsev said: “FAS receives information on a daily basis about price-reduction applications filed or are to be filed by manufacturers to the Ministry of Health Care of the Russian Federation. Also many companies responded to FAS proposal and help the regulator clean up the Price Register from long non-existent drug positions. FAS started investigations of a number of pharmaceutical companies that failed to reduce their prices for HIV-treatment after receiving the official statement from the Antimonopoly Service and expiration of the recommended deadline for filing the relevant applications. Should price registration violations for these drugs be confirmed, the decisions on the earlier approved manufacturer prices for these drugs will be abolished”.

Site Map

News & Events Press Releases Media Releases Image Library About the FAS Russia What We Do General Information Mission, Goals, Values Priority Setting Institutional Memory Stakeholders Engagement Center for Education and Methodics Our History Our Structure Powers of Head and Deputy Heads Our Ratings GCR Using our website International Cooperation Treaties & Agreements International Working Groups Working Group on Research of Competition Issues in the Market of International Telecommunications (Roaming) Meetings Working Group for Studying Competition Problems in the Pharmaceutical Sector Concept Note Meetings OECD Competition Committee OECD meetings 2013 OECD meetings 2014 OECD meetings 2015 OECD meetings 2016 OECD meetings 2017 FAS Annual Reports OECD-GVH RCC RCC Newsletter ICAP Council on Advertising Headquarters for Joint Investigations UNCTAD 13th session IGE UNCTAD Resolution Russian contributions 14th session IGE UNCTAD Resolution Russian contributions 15th session IGE UNCTAD 16th session IGE UNCTAD UN Conference Resolution of the Conference Russian contributions EEU Model Law on Competition ICN BRICS WG (Markets of Social Importance) EU APEC Competition Policy and Law Group Annual meetings Projects ERRA Full Members Organizational Structure Archive Working Group on Investigating Issues on Pricing in the Oil and Oil Product Markets and Methods of their Functioning Meetings Document Library Legislation Reports & Analytics Cases & decisions Contacts Give feedback Contact us Links Authorities Worldwide